Given the deleterious effects of high PAI-1 levels in COVID-19 patients, it is encouraging that the novel therapeutic agent TM5614 that can potentially accelerate the fibrinolytic system could be a treatment option for COVID-19. Here, SERPINE1 is linked to COVID-19.